Ligand Pharmaceuticals | LGND

Stock Price
166.75
Daily Change
-0.99 -0.59%
Monthly
17.10%
Yearly
64.87%
Q3 Forecast
165.37

Peers Price Chg Day Year Date
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Arrowhead Research 29.08 1.08 3.86% 30.87% Sep/05
Baxter International 24.42 0.84 3.56% -37.34% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Glaxosmithkline 40.50 0.89 2.25% -7.26% Sep/05
Insmed 145.10 2.57 1.80% 104.25% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
Ligand Pharmaceuticals 166.75 -0.99 -0.59% 64.87% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
MacroGenics 2.00 0.06 3.09% -38.46% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Pacira 26.45 -0.28 -1.05% 90.97% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Veracyte 32.43 0.91 2.89% 13.51% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US400 3297 16.31 0.50% 12.16% Sep/05

Ligand Pharmaceuticals traded at $166.75 this Friday September 5th, decreasing $0.99 or 0.59 percent since the previous trading session. Looking back, over the last four weeks, Ligand Pharmaceuticals lost 17.10 percent. Over the last 12 months, its price rose by 64.87 percent. Looking ahead, we forecast Ligand Pharmaceuticals to be priced at 165.37 by the end of this quarter and at 161.28 in one year, according to Trading Economics global macro models projections and analysts expectations.

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company. The Company is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company's technology includes Captisol Technology, OmniAb Technologies (OMT), Icagen Ion Channel Technology Platform, Pelican Expression Technology platform and Liver Targeting Prodrug (LTP) Technology to assist companies in their work toward securing prescription drug and biologic approvals. It has partnerships and license agreements with over 130 pharmaceutical and biotechnology companies and over 300 programs that are in various stages of commercialization, development or research and are fully funded by its collaboration partners and licensees. Its partners and licensees have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others.